# OnCo record olaratumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/olaratumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "olaratumab" ;
  schema:name "Olaratumab"@en ;
  schema:alternateName "IMC-3G3"@en, "LY3012207"@en, "Lartruvo" ;
  schema:description "Olaratumab was approved in 2016 with doxorubicin for soft tissue sarcoma after a small trial suggested it added almost a year of life, but the large confirmatory trial found no benefit and it was withdrawn in 2019, a warning case for accelerated approvals."@en ;
  schema:url <https://onco.cc/drugs/olaratumab/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Olaratumab> ;
  schema:citation <https://en.wikipedia.org/wiki/Olaratumab>, <https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2109625> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Anti-PDGFR alpha monoclonal antibody, intravenous" ;
  onco:approval "US 2016: Soft tissue sarcoma not curable by surgery or radiotherapy, with doxorubicin (accelerated approval)" ;
  onco:acceleratedApproval "US 2016-10-19: In combination with doxorubicin for adults with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> .